MPP dihydrochloride | 911295-24-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: MPP dihydrochloride
• 英文别名: 4-[1-(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidin-1-ylethoxy)phenyl]pyrazol-3-yl]phenol;dihydrochloride
• CAS: 911295-24-4
• 化学式: C29H33Cl2N3O3
• 分子量: 542.5
• InChiKey: FWDNPWVVRVSJQH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.63
• 重原子数：
  37
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  70.8
• 氢给体数：
  4
• 氢受体数：
  5

文献信息

• DEUTERO-PHENFORMIN DERIVATIVES
  申请人：Enlibrium Inc

  公开号：US20170210704A1

  公开（公告）日：2017-07-27

  The present disclosure is directed to novel phenformin derivatives, and their pharmaceutically acceptable salts, solvates, or stereoisomers thereof. This disclosure also provides compositions and the use of such compositions in method of treating cancer, diabetes, or polycystic ovarian syndrome.

  本公开涉及新的苯乙双胍衍生物，以及它们的药用可接受的盐、溶剂化物或立体异构体。本公开还提供了此类化合物的组合物及其在治疗癌症、糖尿病或多囊卵巢综合征的方法中的用途。
• Quinolinones as Inhibitors of Translation Initiation Complex
  申请人：Sanford-Burnham Medical Research Institute

  公开号：US20180044324A1

  公开（公告）日：2018-02-15

  Provided herein are compounds and pharmaceutical compositions comprising quinolinones. The quinolinones and compositions thereof are useful as eukaryotic translation initiation factor 4F (eIF4F) complex modulators.

  本文提供了含喹啉酮的化合物和药物组合物。这些喹啉酮及其组合物可用作真核翻译起始因子4F（eIF4F）复合物调节剂。
• SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF HORMONE-DEPENDENT DISEASES
  申请人：UNIVERSITÉ LAVAL

  公开号：US20160200685A1

  公开（公告）日：2016-07-14

  Provided are compounds of general formula A and A′, wherein X 1 and X 2 are each C, CH or N; R 3 and R 4 are each H, optionally substituted C 1 -C 30 saturated or unsaturated chemical group, or together form an optionally substituted C 5 -C 8 cycle; Z 1 ; Z 2 and Z 3 are each N or CH; V is C═O, C═S or CH 2 ; n is from 1 to 12; W 1 and W 2 are each H, CH 2 , O or S; and R 1 and R 2 are each H, Cr 1 C 6 alkyl, C 1 C 6 aryl, C 1 C 12 alkylaryl, optionally substituted phenyl, C 1 C 6 alkoxy, C 1 C 6 thioalkoxy, F, Cl, Br or I. These compounds inhibit steroid sulfatase (STS), act as selective estrogen receptor modulators (SERMs), increase alkaline phosphatase (ALP) activity, and are useful in the treatment of medical conditions involving hormones such as breast cancer, prostate cancer, endometriosis, osteoporosis, benign prostatic hyperplasia and endometrial cancer.

  提供了一般式为A和A'的化合物，其中X1和X2分别为C、CH或N；R3和R4分别为H、可选取代的C1-C30饱和或不饱和化学基团，或共同形成可选取代的C5-C8环；Z1、Z2和Z3分别为N或CH；V为C═O、C═S或CH2；n为1至12；W1和W2分别为H、 、O或S；R1和R2分别为H、Cr1C6烷基、C1C6芳基、C1C12烷基芳基、可选取代的苯基、C1C6烷氧基、C1C6硫代烷氧基、F、Cl、Br或I。这些化合物抑制类固醇磺酸酯酶（STS），作为选择性雌激素受体调节剂（SERMs），增加碱性磷酸酶（ALP）活性，并可用于治疗涉及激素的医疗条件，如乳腺癌、前列腺癌、子宫内膜异位症、骨质疏松症、良性前列腺增生和子宫内膜癌。
• SCREENING METHOD FOR ESTROGENIC AND ANTI-ESTROGENIC ACTIVITY
  申请人：Bundesinstitut Für Risikobewertung

  公开号：EP3517967A1

  公开（公告）日：2019-07-31

  The present invention relates to a cell as deposited under accession number DSM ACC3321 and derivatives thereof. Furthermore, the present invention relates to methods for testing a compound of interest for potential estrogenic or anti-estrogenic activity as well as to methods for testing a cell for its potential to form discontinuous basolateral adherens junctions in presence of an anti-estrogenic compound. The application relates also to uses of a cell capable of forming discontinuous basolateral adherens junctions. The present invention relates furthermore to methods of analysing the morphology of adherens junctions in tissue of a subject and a respective kit.

  本发明涉及登录号为 DSM ACC3321 的细胞及其衍生物。此外，本发明还涉及测试相关化合物的潜在雌激素或抗雌激素活性的方法，以及测试细胞在抗雌激素化合物存在下形成不连续基底侧粘附连接的潜力的方法。本申请还涉及能够形成不连续基底侧粘附连接的细胞的用途。本发明还涉及分析受试者组织中粘连接头形态的方法和相应的试剂盒。
• Quinolinones as inhibitors of translation initiation complex
  申请人：Sanford Burnham Prebys Medical Discovery Institute

  公开号：US10577349B2

  公开（公告）日：2020-03-03

  Provided herein are compounds and pharmaceutical compositions comprising quinolinones. The quinolinones and compositions thereof are useful as eukaryotic translation initiation factor 4F (eIF4F) complex modulators.

  本文提供了包含喹啉酮的化合物和药物组合物。这些喹啉酮类化合物及其组合物可用作真核生物翻译起始因子 4F（eIF4F）复合物调节剂。